• Home
  • Study Details

Investigating whether TOL-3021 can stop autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes

This study investigates whether TOL-3021 can stop the autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes.

Age & Gender

  • 18 years ~ 40 years
  • Male, Female


North Carolina (Statewide)


$100 gift card per completed clinic visit

In-person visits : 22
Total length of participation : 42 months

Looking for Specific Volunteers

Able to participate:

  • Diagnosed with Type I Diabetes within last 5 years
  • Hemoglobin A1c level <7.6%
  • On insulin therapy
  • Willing to wear Dexcom G6 continuous glucose monitoring device throughout trial

Not eligible if:

  • BMI over 32
  • Pregnant or breastfeeding
  • Previous immunotherapy for T1DM
  • Liver disease, kidney disease, cardiac disease, or history of adrenal insufficiency
  • History of organ transplant including beta cell transplant

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

John Buse

Study Topics

Immune System/Infections

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.